1.

Patients’characteristics and univariate analysis of C-SCLC (N=114)

Characteristics	n (%)	MST (month)	OS (%)			χ2	P
			1-year	3-year	5-year
C-SCLC, combinedsmall cell lung carcinoma; MST, median survivaltime; OS, overallsurvival; KPS, Karnofskyperformance score; AJCC, the AmericanJoint Committee on Cancer; VALSG, the Veteran’sAdministration Lung Cancer Study Group; ED, extended disease; LD, limited disease; SCC, squamouscell carcinoma; *, of the 66 patients receiving surgery, 65 patientshad detailed de-scriptions of MLN and resection margin for the analysis of prognostic factors;MLN, metastatic lymph node.
Gender						2.307	0.129
Male	93 (81.6)	22.7	75.3	37.2	32.9
Female	21 (18.4)	82.0	81.0	65.4	54.5
Age (year)						2.384	0.123
≤60	68 (59.6)	34.3	81.2	47.3	41.1
>60	46 (40.4)	18.9	69.7	36.3	32.3
Smoking history						4.772	0.029
Absence	24 (21.1)	82.0	87.5	64.1	56.1
Presence	90 (78.9)	21.5	73.4	36.1	31.5
KPS 21.353	0.000
≥80	101 (88.6)	34.3	82.9	46.7	42.7
<80	13 (11.4)	8.0	30.8	15.4	0.0
Tumor location						0.401	0.527
Central type	92 (80.7)	26.2	76.7	41.2	34.8
Peripheral type	22 (19.3)	26.2	76.4	50.0	50.0
Tumor location						3.092	0.079
Left lung	52 (45.6)	18.1	62.3	39.3	30.5
Right lung	62 (54.4)	34.4	88.3	46.2	43.7
Stage, AJCC 7th 18.010	0.000
I	11 (9.6)	−	100	85.7	85.7
II	22 (19.3)	62.2	85.9	65.6	57.4
III	53 (46.5)	22.7	73.8	35.7	32.7
IV	28 (24.6)	14.3	65.8	21.7	10.9
Stage, VALSG						10.661	0.001
ED	31 (27.2)	14.3	65.8	23.3	11.6
LD	83 (72.8)	37.6	79.3	50.4	45.8
Component						1.656	0.198
SCC	60 (52.6)	37.6	82.1	51.3	43.7
Non-SCC	46 (40.4)	21.5	67.8	35.0	31.1
Chemotherapy						0.364	0.547
Yes	96 (84.2)	26.5	79.1	42.4	37.7
No	18 (15.8)	18.9	62.9	47.2	35.4
Radiotherapy						0.234	0.629
Yes	48 (42.1)	32.2	82.8	42.4	35.3
No	66 (57.9)	22.7	71.7	42.4	37.6